A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma.

A study of human tumor cells implanted in mice from the MacPherson Lab at Fred Hutch describes a new way to screen for the ...

A recent study published in Engineering has shed new light on the mechanisms underlying the metastasis of head and neck squamous cell carcinoma (HNSCC).

Oral squamous cell carcinoma (OSCC) is a leading cause of cancer-related deaths, and early detection is key to improving ...

The strong results of KEYNOTE-689 and likely FDA approval of pembrolizumab for perioperative HNSCC raise both concerns and ...

Ravindra Uppaluri, MD, PhD, discussed the KEYNOTE-689 trial, which investigated pembrolizumab in locally advanced head and ...

Pembrolizumab combo before/after surgery and radiation significantly improved event-free survival in resectable advanced head ...

From a meeting that celebrates basic research and being "first," a look at 3 data sets on therapies that would break new ...

Pembrolizumab (Keytruda) given before and after surgery to supplement adjuvant therapy improved responses and survival in ...

A reduced dose of elective radiation is safe and does not compromise treatment efficacy in patients with head and neck ...